DUSA PHARMACEUTICALS, INC.
NASDAQ : DUSA

DUSA PHARMACEUTICALS, INC.

August 28, 2007 08:01 ET

DUSA Pharmaceuticals to Present at Roth Capital Partners 2007 New York Conference

WILMINGTON, MASSACHUSETTS--(Marketwire - Aug. 28, 2007) - DUSA Pharmaceuticals, Inc.® (NASDAQ GM:DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions today announced that Bob Doman, President & CEO will present at the Roth Capital Partners Annual New York Institutional Investor Conference. The conference is being held at the Westin New York at Times Square on September 5-6, 2007. Mr. Doman is scheduled to present at 4:00 p.m. Eastern Time on Wednesday, September 5.

Investors may listen to the live webcast and view a copy of the slide presentation online via the "Investors" section of the Company's web site at www.dusapharma.com. The recorded webcast will be accessible online for at least 30 days. Attendance at the Roth Capital Partners 2007 New York Conference is by invitation only.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or Grade 2 actinic keratoses of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReach™, Nicomide® and the AVAR® line. DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, MA. Please visit the company's website at www.dusapharma.com for more information.

Contact Information

  • DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (978) 657-7500 Ext. 1121
    Website: www.dusapharma.com
    or
    The Trout Group LLC
    Chad Rubin
    Investor Relations Contact
    (646) 378-2947